The Production Base of Nanjing Vcare , Tianshu Pharmaceutical, Obtained Two Active Pharmaceutical Ingredient (API) Registration Numbers for the First Time

2024-08-15

Recently, Hubei Tianshu Pharmaceutical Co., Ltd. ("Tianshu Pharmaceutical"), the production base affiliated with Nanjing Vcare, received the acceptance notices for two API varieties, namely dapagliflozin and vonoprazan fumarate, issued by the Center for Drug Evaluation of the National Medical Products Administration, and successfully obtained the registration numbers.

 

 

The first successful registration of the two API varieties, Dapagliflozin and Vonoprazan fumarate, by Tianshu Pharmaceutical is another important milestone following the enterprise's smooth acquisition of the "Drug Production License" in December 2023. It marks that Tianshu Pharmaceutical has officially entered the field of the API CDMO supply pool and also strongly verifies that Tianshu Pharmaceutical plays an important role in the one-stop CRO/CDMO whole industrial chain layout of "chemistry + pharmacy + medicine" created by Nanjing Vcare. In the future, relying on the strong R&D and technological innovation capabilities of Nanjing Vcare, Tianshu Pharmaceutical will continue to enhance its service capabilities across the entire pharmaceutical industrial chain.

Nanjing Vcare will continue to focus deeply on the R&D and production service model covering the whole industrial chain and the whole life cycle of chemical drugs. It is committed to providing customers with pharmaceutical and clinical CRO services for innovative drugs and generic drugs. Meanwhile, it will ensure the associated supply of products such as APIs, intermediates and impurities of relevant varieties to fully guarantee the stable production of customers throughout the whole life cycle.

Prev

Nanjing Vcare Won the "Best Ecological Partner" Award from Lunan Pharmaceutical

Next

A Delegation Led by the Global Vice President of Thermo Fisher Scientific Visited Nanjing Vcare